A phase I/IIa study assessing single and multiple doses of IDX21437 in healthy and HCV-infected subjects
Latest Information Update: 13 May 2022
At a glance
- Drugs Uprifosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 16 Mar 2019 Sfaety results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.